Patents Assigned to AstraZeneca
  • Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors
    Publication number: 20110224273
    Abstract: A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11?HSD1, processes for making them and pharmaceutical compositions comprising them are also described.
    Type: Application
    Filed: September 9, 2010
    Publication date: September 15, 2011
    Applicant: AstraZeneca AB
    Inventors: Martin John Packer, James Stewart Scott, Andrew Stocker, Paul Robert Owen Whittamore
  • Novel Crystalline Form
    Publication number: 20110224229
    Abstract: Crystalline Forms of 6-[2-(4-cyano-phenyl)-2H-pyrazol-3-yl]-5-methyl-3-oxo-4-(3-trifluoromethyl-phenyl)-3,4-dihydro-pyrazine-2-carboxylic acid ethylamide are disclosed together with processes for preparing the Forms, pharmaceutical compositions comprising the Forms, and the use of the Forms in therapy.
    Type: Application
    Filed: March 9, 2011
    Publication date: September 15, 2011
    Applicant: AstraZeneca AB
    Inventor: Martin Lindsjö
  • CRYSTALLINE FORM OF 4-(5--4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PYRIDINE
    Publication number: 20110224261
    Abstract: The present invention relates to a novel crystalline form of 4-(5-{(IR)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine. Further, the present invention also relates to the use of the novel crystalline form for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it.
    Type: Application
    Filed: August 11, 2009
    Publication date: September 15, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Hans Åström, Alexander Minidis, Veronica Profir
  • Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
    Patent number: 8017785
    Abstract: Phosphoric acid, edisylic acid (1,2-ethanedisulfonic acid), citric acid, orotic acid (uracil-6-carboxylic acid), R-mandelic acid, sulfuric acid, 1,5-naphthalenedisulfonic acid, D-aspartic acid, and lysine monohydrochloride salts of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine, and methods for their preparation, pharmaceutical compositions comprising said salts, and use, are disclosed. The salts can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: September 13, 2011
    Assignees: AstraZeneca AB, Targacept, Inc.
    Inventors: Caroline Ericsson, Martin Bohlin, Tesfai Sebhatu, Gary M. Dull, Julio A. Munoz, Craig H. Miller
  • N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy
    Patent number: 8017602
    Abstract: The present invention provides a compound of formula (I) wherein W, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: September 13, 2011
    Assignee: AstraZeneca AB
    Inventors: Roger Victor Bonnert, Stephen Connolly, Anthony Ronald Cook, Richard Evans, Piotr Raubo
  • Pyrimido [4,5-B]-oxazines for use as DGAT inhibitors
    Patent number: 8017603
    Abstract: Compounds of formula (I) or salts thereof, wherein A, and R1 to R5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: September 13, 2011
    Assignee: AstraZeneca AB
    Inventors: Alan Martin Birch, Paul David Kemmitt
  • Pyridine and pyrazine derivatives -083
    Patent number: 8017611
    Abstract: The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G1, G2, G3, G4, J, Ring A, n and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: September 13, 2011
    Assignee: AstraZeneca AB
    Inventors: Bernard Christophe Barlaam, Craig Steven Harris, Christine Marie Paul Lambert, Gilles Ouvry, Justin Fairfield Bower, Benedicte Delouvrie, Gary Fairley, Jon James Gordon Winter
  • Novel triazolo pyrimidine compounds
    Publication number: 20110218330
    Abstract: The present invention relates to a pyrimidine compound (I) useful as a pharmaceutical intermediate, to a process for preparing said pyrimidine compound, to intermediates used in said process, and to the use of said pyrimidine compound in the preparation of pharmaceuticals.
    Type: Application
    Filed: March 24, 2011
    Publication date: September 8, 2011
    Applicant: AstraZeneca AB
    Inventors: Ulf Larsson, Mattias Magnusson, Tibor Musil, Andreas Palmgren
  • CHEMICAL COMPOUNDS 251
    Publication number: 20110218182
    Abstract: The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.
    Type: Application
    Filed: July 2, 2009
    Publication date: September 8, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Leslie Dakin, James Edward Dowling, Michelle Lamb, Jon Read, Qibin Su, Xiaolan Zheng
  • Compounds and their uses 707
    Patent number: 8012979
    Abstract: The present invention relates to isoquinolinone derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: September 6, 2011
    Assignee: AstraZeneca AB
    Inventors: Matthew Hallam, Barrie Martin, Piotr Raubo, Bryan Roberts, Stephen St-Gallay, Paul Willis
  • 9-substituted 8-oxoadenine compound
    Patent number: 8012964
    Abstract: The present invention provides an 8-oxoadenine compound having immunemodulating activities such as an interferon inducing activity and useful as an antiviral agent and antiallergic agent, which is represented by the following formula (1): [wherein the ring A represents a 6-10 membered aromatic carbocyclic ring and the like, R represents a halogen atom, an alkyl group and the like, n represents an integer of 0-2, Z1 represents alkylene, X2 represents oxygen atom, sulfur atom, SO2, NR5, CO, CONR5, NR5CO and the like, Y1, Y2 and Y3 represent independently a single bond or an alkylene group, X1 represents oxygen atom, sulfur atom, NR4 (R4 is hydrogen atom or an alkyl group) or a single bond, R2 represents a substituted or unsubstituted alkyl group, R1 represents hydrogen atom, hydroxy group, an alkoxy group, an alkoxycarbonyl group or a haloalkyl group] or its pharmaceutically acceptable salt.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: September 6, 2011
    Assignees: Dainippon Sumitomo Pharma Co., Ltd., Astrazeneca Aktiebolag
    Inventors: Ayumu Kurimoto, Yoshiaki Isobe, Stephen Brough, Hiroki Wada, Roger Bonnert, Thomas McInally
  • Isoquinolinone derivatives
    Patent number: 8012980
    Abstract: The present invention relates to isoquinolinone derivatives of formula (I): wherein are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: September 6, 2011
    Assignee: AstraZeneca AB
    Inventors: Stephen John Brough, Timothy Jon Luker, Bryan Glyn Roberts, Stephen Anthony St-Gallay
  • Ethanamine compounds and methods of using the same 545
    Patent number: 8013165
    Abstract: The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: September 6, 2011
    Assignee: AstraZeneca AB
    Inventors: Michael Balestra, Peter Bernstein, Glen E. Ernst, William Frietze, John P McCauley, Lihong Shen, David Nugiel
  • Elastin peptide fingerprints and analysis methods for MMP12 related to COPD
    Patent number: 8012692
    Abstract: Methods for producing and using protein/peptide fingerprints, allowing identification and investigation of disease-associated proteins/peptides that can be linked to specific drug targets, or to specific drug target combinations. The methods are particularly useful for studies relating to Chronic Obstructive Pulmonary Disease (COPD), especially for the enzyme MMP12.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: September 6, 2011
    Assignee: AstraZeneca AB
    Inventors: Per Broberg, Thomas Fehniger, György Marko-Varga, Stephan Uebel
  • BINDING MEMBERS FOR IGE MOLECULES
    Publication number: 20110212084
    Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.
    Type: Application
    Filed: February 15, 2008
    Publication date: September 1, 2011
    Applicants: ASTRAZENECA AB, MEDIMMUNE LIMITED
    Inventors: Duncan Cochrane, Suzanne Cohen, Louise Claire Dobson, Fredick Per-Olof Eriksson, David Phillip Monk, Karin Von-Wachenfeldt
  • Combination of ZD6474 and Pemetrexed
    Publication number: 20110212978
    Abstract: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of ZD6474 in combination with pemetrexed; to a pharmaceutical composition comprising ZD6474 and pemetrexed; to a combination product comprising ZD6474 and pemetrexed for use in a method of treatment of a human or animal body by therapy; to a kit comprising ZD6474 and pemetrexed; to the use of ZD6474 and pemetrexed in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.
    Type: Application
    Filed: September 28, 2010
    Publication date: September 1, 2011
    Applicant: AstraZeneca AB
    Inventors: Anderson Joseph Ryan, Stephen Robert Wedge
  • Biphenyl derivatives and their use in treating hepatitis C
    Patent number: 8008303
    Abstract: Use of a compound which is a biphenyl derivative of formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of Hepatitis C wherein the variables are described herein.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: August 30, 2011
    Assignee: AstraZeneca AB
    Inventors: Christopher James Wheelhouse, Alexander James Floyd Thomas, David John Bushnell, James Lumley, James Iain Salter, Malcolm Clive Carter, Neil Mathews, Christopher John Pilkington, Richard Martyn Angell
  • Compound—827
    Patent number: 8008279
    Abstract: The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases, including cathepsins B, K, C, F, H, L, O, S, W and X. Of particular interest are diseases associated with Cathepsin K.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: August 30, 2011
    Assignee: AstraZeneca AB
    Inventors: Alexander Graham Dossetter, Nicola Murdoch Heron
  • Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
    Patent number: 8008350
    Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: August 30, 2011
    Assignee: AstraZeneca AB
    Inventors: Timothy Jon Luker, Rukhsana Tasneem Mohammed, Mark Dickinson, Stephen Thom
  • Citrate salt of an indole derivative and its pharmaceutical use
    Patent number: 8008294
    Abstract: The salt, the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, a process for its preparation, pharmaceutical formulations containing it and the use of it in therapy, and particularly in the therapy of GSK3 related conditions and disorders.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: August 30, 2011
    Assignee: AstraZeneca AB
    Inventors: Tesfai Sebhatu, Erica Ståhle